Efficacy of various polymer:drug ratios of molecularly homogeneous implants in preventing herpes simplex virus type-2 infection in Vero cells
Loading...
Links to Files
Permanent Link
Author/Creator
Author/Creator ORCID
Date
2014-02-07
Type of Work
Department
Towson University. Department of Biological Sciences
Program
Citation of Original Publication
Rights
Copyright protected, all rights reserved.
There are no restrictions on access to this document. An internet release form signed by the author to display this document online is on file with Towson University Special Collections and Archives.
There are no restrictions on access to this document. An internet release form signed by the author to display this document online is on file with Towson University Special Collections and Archives.
Subjects
Abstract
Genital herpes, which is typically caused by HSV-2, infects 15-25% of the population worldwide. Infection results in recurrent outbreaks of lesions in the genital area. There is no cure for herpes, but anti-herpetics have been developed to combat infection. These drugs have a low oral bioavailability, a short half-life, and poor patient compliance. To negate these issues, the TUHVL has developed an implant made with drug and the biodegradable polymer polycaprolactone (PCL). However, the ideal ratio of polymer:drug has not been established. This study aims to determine which ratio has the best release kinetics and antiviral activity. Implants were created with various polymer:drug ratios and an in vitro study was performed. Samples were collected and analyzed with HPLC to determine the release kinetics. The antiviral effectiveness was determined by monitoring cytopathic effect and plaque assays. Ultimately, we found that the 75:25 PCV implants were the most effective.